Literature DB >> 15956247

Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.

Yin Li1, Yuehua Mao, Paul W Brandt-Rauf, Ann C Williams, Robert L Fine.   

Abstract

PRIMA-1 (p53 reactivation and induction of massive apoptosis) is a chemical compound that was originally identified as a selective mutant p53-dependent growth suppressor by screening a library of low-molecular-weight compounds. However, its mechanism of action is unknown. In this study, we examined toxicity of PRIMA-1 to three premalignant human colorectal adenoma cell lines (RG/C2, BR/C1, and AA/C1) and four colorectal carcinoma cell lines (DLD-1, SW480, LOVO, and HCT116) and its mechanism of action. It selectively induced apoptosis only in the mutant p53 premalignant and malignant colon cell lines, but was not toxic to the wild-type p53 premalignant and malignant colon cell lines. Using stable transfectants of temperature-sensitive p53 mutant Ala(143) in null p53 H1299 lung cancer cells, we found that PRIMA-1 induced significantly more apoptosis in cells with mutant p53 conformation (37 degrees C) than the wild-type p53 conformation (32.5 degrees C). Cell cycle analysis indicated that its inhibition of cell growth was correlated with induction of G(2) arrest. Western blot analysis showed PRIMA-1 increased p21 and GADD45 expression selectively in the mutant p53 cells. However, Fas, Bcl-2 family proteins, and caspases were not involved in PRIMA-1-induced cell death. The c-Jun-NH(2)-kinase (JNK) inhibitor SP 600125, but not p38 mitogen-activated protein kinase inhibitor SB 203580 or extracellular signal-regulated kinase inhibitor PD 98059, blocked PRIMA-1-induced apoptosis. Transfection with a dominant-negative phosphorylation mutant JNK, but not a dominant-negative p38 or wild-type JNK, inhibited PRIMA-1-induced cell death, suggesting that the JNK pathway plays an important role in PRIMA-1-induced apoptosis. PRIMA-1 is a highly selective small molecule toxic to p53 mutant cells and may serve as a prototype for the development of new p53-targeting agents for therapy of premalignant and malignant cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956247     DOI: 10.1158/1535-7163.MCT-04-0206

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  15 in total

1.  Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Authors:  Chinthalapally V Rao; Jagan Mohan R Patlolla; Li Qian; Yuting Zhang; Misty Brewer; Altaf Mohammed; Dhimant Desai; Shantu Amin; Stan Lightfoot; Levy Kopelovich
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

Review 2.  p53-based therapeutics for head and neck squamous cell carcinoma.

Authors:  Patrick Tassone; Matthew Old; Theodoros N Teknos; Quintin Pan
Journal:  Oral Oncol       Date:  2013-04-25       Impact factor: 5.337

3.  The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.

Authors:  Roza Zandi; Kai Xu; Hans S Poulsen; Jack A Roth; Lin Ji
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

Review 4.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

6.  MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.

Authors:  Wenrui Duan; Li Gao; Xin Wu; Li Wang; Serge P Nana-Sinkam; Gregory A Otterson; Miguel A Villalona-Calero
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

7.  Activations of Both Extrinsic and Intrinsic Pathways in HCT 116 Human Colorectal Cancer Cells Contribute to Apoptosis through p53-Mediated ATM/Fas Signaling by Emilia sonchifolia Extract, a Folklore Medicinal Plant.

Authors:  Yu-Hsuan Lan; Jo-Hua Chiang; Wen-Wen Huang; Chi-Cheng Lu; Jing-Gung Chung; Tian-Shung Wu; Jia-Hua Jhan; Kuei-Li Lin; Shu-Jen Pai; Yu-Jen Chiu; Minoru Tsuzuki; Jai-Sing Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-28       Impact factor: 2.629

8.  Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.

Authors:  M Farhat; A Poissonnier; A Hamze; C Ouk-Martin; J-D Brion; M Alami; J Feuillard; C Jayat-Vignoles
Journal:  Cell Death Dis       Date:  2014-05-01       Impact factor: 8.469

9.  PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.

Authors:  Thomas Grellety; Audrey Laroche-Clary; Vanessa Chaire; Pauline Lagarde; Frédéric Chibon; Agnes Neuville; Antoine Italiano
Journal:  BMC Cancer       Date:  2015-10-13       Impact factor: 4.430

10.  PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.

Authors:  Noriko Kobayashi; Mohammadreza Abedini; Noriaki Sakuragi; Benjamin K Tsang
Journal:  J Ovarian Res       Date:  2013-01-26       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.